Xenetic Biosciences, Inc.
Advancing DNase & CAR T immune-oncology platforms to treat hard-to-treat cancers.
XBIO | NDAQ
Overview
Corporate Details
- ISIN(s):
- US9840155033
- LEI:
- Country:
- United States of America
- Address:
- 945 CONCORD ST., 1701 FRAMINGHAM
- Website:
- https://www.xeneticbio.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Xenetic Biosciences, Inc. is a biopharmaceutical company focused on advancing proprietary technology platforms in immune-oncology to address hard-to-treat cancers. The company's core development is centered on its DNase-based oncology platform, which aims to improve the efficacy of cancer therapies by targeting Neutrophil Extracellular Traps (NETs). NETs are recognized as a driver of cancer progression, metastasis, and resistance to treatments such as chemotherapy and checkpoint inhibitors. The company is also developing XCART, a personalized CAR T platform technology, to target multiple high-value cancer indications, including pancreatic cancer and other solid tumors.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Xenetic Biosciences, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Xenetic Biosciences, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Xenetic Biosciences, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
